References

  1. Contin-Bordes C, Lazaro E, Pellegrin JL, Viallard JF, Moreau JF, Blanco P. Systemic lupus erythematosus: from pathophysiology to treatment. Rev Med interne. 2009; 30(12):9-13. PubMed | Google Scholar

  2. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford). 2003; 42(2):230-4. PubMed | Google Scholar

  3. Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology. 2007; 12(3): 257-261. PubMed | Google Scholar

  4. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Practice and Research Clinical Rheumatology. 2005; 19(5):685-708. PubMed | Google Scholar

  5. Vilá LM, Alarcón GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD. Lumina Study Group, Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum. 2006; 55(5):799-806. PubMed | Google Scholar

  6. Jallouli M, Frigui M, Marzouk S, Feki H, Kaddour N, Bahloul Z. Mortality and prognostic factors in 146 patients with systemic lupus erythematosus in southern Tunisia. Presse Med. 2008; 37(12):1711-1716. PubMed | Google Scholar

  7. Yu H-H, Wang L-C, Lee J-H, Lee C-C, Yang Y-H, Chiang B-L. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients. Rheumatology (Oxford). 2007; 46(9):1492-1494. PubMed | Google Scholar

  8. Ng WL, Chu CM, Wu AK, Cheng VC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. Q J Med. 2006; 99(1):37-47. PubMed | Google Scholar

  9. Ward MM, Studenski S. Age associated clinical manifestations of systemic lupus erythematosus: a multivariate regression analysis. J Rheumatol. 1990; 17(4):476-481. PubMed | Google Scholar

  10. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, Roubey RA, Dooley MA. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus. 2002; 11(3):161-167. PubMed | Google Scholar

  11. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics.” Medicine (Baltimore). 2004; 83(1):1-17. PubMed | Google Scholar

  12. Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford). 2001; 40(7):750-756. PubMed | Google Scholar

  13. Nakabayashi K, Arimura Y, Yoshida M, Nagasawa T. Anti-T cell antibodies in primary glomerulonephritis. Clin Nephrol. 1985; 23(2):74-80. PubMed | Google Scholar

  14. Boffa JJ, Rougier JP, Noel N, Ronco P. High cardiovascular complications in systemic lupus erythematosus: Physiopathology and risk management. Nephrol Ther. 2009; 5(7):595-602. PubMed | Google Scholar

  15. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009; 60(8):2428-2437. PubMed | Google Scholar

  16. Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther. 2009; 11(6):R186. PubMed | Google Scholar

  17. Huang YL, Chung HT, Chang CJ, Yeh KW, Chen LC, Huang JL. Lymphopenia Is a Risk Factor in the Progression of Carotid Intima-Media Thickness in Juvenile-Onset Systemic Lupus Erythematosus. Arthritis Rheum. 2009; 60(12):3766-3775. PubMed | Google Scholar

  18. Wenzel J, Gerdsen R, Uerlich M, Bauer R, Tueting T, Bieber T. Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. Br J Dermatol. 2004; 150(5): 994-998. PubMed | Google Scholar

  19. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford). 2000; 39(12):1316-1319. PubMed | Google Scholar

  20. Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus. 2003; 12(1):8-14. PubMed | Google Scholar

  21. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28 T cells in systemic lupus erythematosus (SLE) and the relation with activation- induced apoptosis. Clin Exp Immunol. 1996; 106(2):218-229. PubMed | Google Scholar